Literature DB >> 1469654

Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono- and polysaccharide derivatives.

T Fujita1, M Nishikawa, C Tamaki, Y Takakura, M Hashida, H Sezaki.   

Abstract

Four types of superoxide dismutase (SOD) derivatives such as SOD-carboxymethyl dextran conjugate, SOD-diethylaminoethyl dextran conjugate, galactosylated SOD and mannosylated SOD were synthesized and their potential for selective targeting to organs or cells was evaluated in mice by pharmacokinetic analysis. All SOD derivatives retained 50 to 80% of the original enzymatic activity and were stable during incubation with mouse serum retaining enzymatic activity greater than 80% for 3 hr. After intravenous injection, native SOD was rapidly excreted into urine and no significant accumulation was observed in the organs except the kidney. SOD-carboxymethyl dextran conjugate gave a long plasma half-life because of impaired glomerular filtration and tissue interaction. By contrast, galactosylated-SOD and mannosylated-SOD were very rapidly eliminated from the circulation and taken up by parenchymal and nonparenchymal cells of the liver, respectively, via receptor-mediated endocytosis. These uptake processes were nonlinear and hepatic uptake clearance decreased as the dose increased, although almost complete extraction was obtained at a dose of 0.1 mg/kg. Furthermore, the accumulation in kidney of both glycosylated SODs was drastically decreased due to reduced renal proximal tubular reabsorption and also enhanced hepatic clearance. SOD-diethylaminoethyl dextran conjugate also rapidly disappeared from plasma and distributed into liver, but its accumulation occurred due to electrostatic interaction and was nonspecific in cellular distribution. These results suggest the possibility of controlling the in vivo fate of SOD at a cellular level by chemical modification utilizing sugar moieties with varied physicochemical and/or biological characteristics.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1469654

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

Review 1.  Endocytic mechanisms for targeted drug delivery.

Authors:  Lisa M Bareford; Peter W Swaan
Journal:  Adv Drug Deliv Rev       Date:  2007-06-28       Impact factor: 15.470

2.  Development and pharmacokinetics of galactosylated poly-L-glutamic acid as a biodegradable carrier for liver-specific drug delivery.

Authors:  H Hirabayashi; M Nishikawa; Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

Review 3.  Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution.

Authors:  Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1996-06       Impact factor: 4.200

4.  Liver targeting of interferon through pullulan conjugation.

Authors:  K Xi; Y Tabata; K Uno; M Yoshimoto; T Kishida; Y Sokawa; Y Ikada
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

5.  Non-polarized secretion of mouse interferon-beta from gene-transferred human intestinal Caco-2 cells.

Authors:  K Kawabata; M Kondo; Y Watanabe; Y Takakura; M Hashida
Journal:  Pharm Res       Date:  1997-04       Impact factor: 4.200

6.  Inhibition of experimental hepatic metastasis by targeted delivery of catalase in mice.

Authors:  Makiya Nishikawa; Ayumi Tamada; Kenji Hyoudou; Yukari Umeyama; Yuki Takahashi; Yuki Kobayashi; Hitomi Kumai; Emi Ishida; Frantisek Staud; Yoshiyuki Yabe; Yoshinobu Takakura; Fumiyoshi Yamashita; Mitsuru Hashida
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

7.  Immunotargeting of antioxidant enzyme to the pulmonary endothelium.

Authors:  V R Muzykantov; E N Atochina; H Ischiropoulos; S M Danilov; A B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

8.  Disposition characteristics of protein drugs in the perfused rat kidney.

Authors:  K Mihara; T Hojo; M Fujikawa; Y Takakura; H Sezaki; M Hashida
Journal:  Pharm Res       Date:  1993-06       Impact factor: 4.200

9.  Development of glycosylated human interleukin-1alpha, neoglyco IL-1alpha, coupled with D-galactose monosaccharide: biological activities in vivo.

Authors:  S Nabeshima; T Chiba; Y Takei; A Ono; K Moriya; K Onozaki
Journal:  Glycoconj J       Date:  1998-05       Impact factor: 2.916

10.  Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting.

Authors:  M Nishikawa; A Kamijo; T Fujita; Y Takakura; H Sezaki; M Hashida
Journal:  Pharm Res       Date:  1993-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.